The Methodist Hospital Research Institute
Trial Pipeline
Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells
NCT06798623
Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection
NCT07383649
Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer
NCT07042685
Bone Stimulator for Spondylolysis
NCT06666608
VoiceLove Digital Therapy for Delirium in the ICU
NCT07218484
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
NCT07050771
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
NCT07182279
Intraosseous (IO) Cefazolin and Vancomycin in Primary Total Knee Arthroplasty (TKA)
NCT06640491
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
NCT06887218
Non-invasive VNS in Stroke Recovery
NCT06761404
Prehabilitation for Kidney Transplant Candidates
NCT06886256
Blood Flow Restriction (BFR) Training on the Ulnar Collateral Ligament (UCL)
NCT06664827
Personalized Transcranial Direct Current Stimulation in Stroke Recovery
NCT06286800
Home Tele Rehabilitation Therapy for Vascular Dementia
NCT06289569
Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer
NCT06833866
Intraosseous vs. Intravenous Vancomycin Administration in Total Ankle Arthroplasty
NCT06384651
Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
NCT06821100
Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer
NCT06566443
Intraosseous Morphine Administration During Anterior Cruciate Ligament Reconstruction
NCT06511232
Augmenting Rehabilitation Outcomes and Functional Neuroplasticity Using Epidural Stimulation of Cervical Spinal Cord
NCT06225245
ATRA and Carfilzomib in Plasma Cell Myeloma Patients
NCT06536413
MRI Guided Management of Occlusive Peripheral Arterial Disease
NCT06782100
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
NCT07290491
CBD for Pain Following Orthopedic Shoulder Surgery
NCT06381791
IL-2 Plus Abatacept in FTD
NCT06395038
Endoscopic Sleeve Gastroplasty (ESG) for the Treatment of Obesity
NCT06339320
Protein Supplementation After ACL Surgery
NCT06311058
rTMS in Overactive Bladder
NCT06198439
Harnessing Neuroplasticity of Postural Sensorimotor Networks Using Non-Invasive Spinal Neuromodulation to Maximize Functional Recovery After Spinal Cord Injury
NCT06213012
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS
NCT06072703
Venous Ethanol for Ventricular Tachycardia
NCT05511246
Systemic and Central Inflammation in AD
NCT06384378
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
NCT05185505
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
NCT05660083
Phase II Clinical Trial of Interleukin-2 in AD
NCT06096090
LSTR in Chevron Osteotomy
NCT06486753
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
NCT05305924
Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
NCT06258551
Effect of BFR Rehab After Achilles Tendon Rupture
NCT06254794
Limb Occlusion Pressure Tourniquets to Decrease Pain After Surgery
NCT04390425
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
NCT03603405
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
NCT01913106
IO Vancomycin in TSA
NCT05831774
Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer
NCT05241340
Study in ALS With Abatacept & IL-2
NCT06307301
Neoadjuvant Atezolizumab in Cutaneous Melanoma
NCT04020809
Durvalumab with Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
NCT03820141
ORIF Distal Radius Blood Flow Restriction Therapy
NCT06136286
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
NCT03742245
Phase Ib of L-NMMA and Pembrolizumab
NCT03236935
Mesenchymal Stromal Cells in Living Donor Kidney Transplantation
NCT03478215
Feasibility and Acceptability of ReCognitionVR-based Cognitive Stimulation in Surgical Patients
NCT06232317
Neuromuscular Training in Female Youth Soccer
NCT06136299
Opioid Use After Thyroid and Parathyroid Surgeries
NCT04955444
Explore Transplant at Home: Improving Low-Income ESRD Patients' Transplant Knowledge
NCT02268682
Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder
NCT03033355
Ciprofloxacin for Prevention of BK Infection
NCT01789203
A Trial of Esophageal and Gastric Stenting for Leak or Perforation
NCT01107249
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
NCT00445042
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 42 |
| Phase 3 | 28 |
| Phase 4 | 5 |
What the Pipeline for The Methodist Hospital Research Institute Shows
According to the ClinicalTrials.gov registry, The Methodist Hospital Research Institute is linked to 203 US clinical trials across every stage of research activity. Of those, 186 studies are currently recruiting — about 92% of the sponsor's indexed portfolio — and 8 are already marked complete, representing roughly 4% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for The Methodist Hospital Research Institute reports 33 late-stage studies (Phase 3 and Phase 4 combined) and 57 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for The Methodist Hospital Research Institute is HER2-negative Breast Cancer with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.